Ustekinumab for type 1 diabetes in adolescents: a multicenter, double-blind, randomized phase 2 trial.

Name: Αlpha¹ Rigor Record — Ustekinumab for type 1 diabetes in adolescents: a multicenter, double-blind, randomized phase 2 trial.
Item: Ustekinumab for type 1 diabetes in adolescents: a multicenter, double-blind, randomized phase 2 trial.
Rating: 100
Author: Αlpha¹

Tatovic D, Marwaha A, Taylor P, Hanna SJ, Carter K, Cheung WY, Luzio S, Dunseath G, Hutchings HA, Holland G, Hiles S, Fegan G, Williams E, Yang JHM, Domingo-Vila C, Pollock E, Wadud M, Ward-Hartstonge K, Marques-Jones S, Bowen-Morris J, Stenson R, Levings MK, Gregory JW, Tree TIM, Dayan C, USTEKID Study Group

Paper source

Read full text (PMC)

Embed this Rigor badge

Αlpha¹ Rigor Review — 3★ (Adequate), 0 critical, 0 high issues for “Ustekinumab for type 1 diabetes in adolescents: a multicenter, double-blind, randomized phase 2 trial.”

Links back to this Rigor Record.

Αlpha¹ Editorial

This rigor review was examined and confirmed by Αlpha¹ Editorial · August 16, 2026

Αlpha¹ Rigor Review

Rigor Reviewed

3 / 5

Adequate — real issues to address

Interventional Study

Critical

High-priority

How this rating was calculated▸

Started at 5★ — deductions

IntegrityIntegrity concern ×2−1★
ClaimsEfficacy rests on an unvalidated surrogate endpoint−0.5★
ClaimsTreatment effect not shown to be clinically meaningful−0.5★

Model-reported confidence: highReviewer agreement: highEngine: 7.39.0Source: full text

Not verified in this report

The numeric-impossibility checks (GRIM/GRIMMER/DEBIT/SPRITE) did not run: 6 reported means were read, and their group size is not stated where the values are printed (this source has no machine-readable table structure). These checks need the count the mean was averaged over, so none was performed.

Problems surfaced4 types

Numerical inconsistencies1

Values that contradict each other or are impossible for the stated sample: recomputed p-values and test statistics, GRIM/GRIMMER checks on summary numbers, percentages against their own counts, totals against their parts, and estimates against their own confidence intervals.

Internal contradictions in the reported numbersAssessed

Overstated conclusions3

Conclusions that reach past what the paper's own results support — including a significance claim that no longer holds when the statistic is recomputed, and efficacy resting on an unvalidated surrogate endpoint.

Efficacy rests on an unvalidated surrogate endpointAssessed
Treatment effect not shown to be clinically meaningfulAssessed
Conclusions only partially backed by the presented evidenceAssessed

This Αlpha¹ Rigor Review uses AI Rigor Reviewers trained on a curated corpus of high-fidelity and retracted papers, with expert supervision and curation. It can still make mistakes; verify each finding against the source before relying on it.

This is a well-conducted and transparently reported phase 2 randomized controlled trial. The design, ethics, and statistical reporting are strong, with clear documentation of randomization, blinding, power, and missing data handling. Minor reporting gaps exist around code sharing and a few copyedit issues, but no substantive rigor concerns were identified.

Both reviewers independently scored all eight dimensions and agreed on every status; no divergence required reconciliation. The statistics verification recomputed 6 tests consistently, but coverage is partial (only tests with test statistics/df or effect+CI); other p-values remain unverified. Citation check found no retracted or unresolved references. The integrity check noted two low-severity internal contradictions (participant counts) that are plausibly explained by missing data.

7 major claims checked against the paper's own evidence: 3 only partially supported (evidence backs part of the claim; gaps or caveats remain); the rest adequately supported.

Premise concern: surrogate not validated for clinical benefit; effect size not shown to be clinically meaningful.

Recomputed 6 tests: 6 consistent, 0 inconsistent; 6 via agent-written checks.

2 integrity concerns flagged (0 high).

Reporting

Eight Dimensions8 pass

The introduction cites prior studies on T cell subsets, IL-17, and ustekinumab's safety profile, and acknowledges conflicting evidence and the lack of a placebo arm in the pilot study. The rationale linking IL-12/IL-23 inhibition to preservation of C-peptide is well articulated. Limitations of prior research are addressed by the randomized placebo-controlled design.

Sub-criteria

prior work citedADEQUATE

premise rationaleADEQUATE

limitations addressedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The paper establishes a clear scientific premise with extensive prior work and a logical rationale for targeting IL-12/IL-23 in T1D.

Evidence

direct quote[Introduction, paragraphs 2-4]

“There has previously been conflicting evidence for the role of CD4 T helper cells producing IL-17 (T H 17 cells) in T1D”